Biogen Celebrates As EPO Upholds Tecfidera Patent
But Firm Warns Of Ongoing Generic Challenges As Biosimilars Growth Muted In Q3
Biogen has struck another blow against European generic competitors to Tecfidera, after the European Patent Office upheld a dosage patent for the brand that runs until February 2028. Meanwhile, the firm reported flat biosimilars sales in the third quarter of 2024.
